Journal
JAMA Network Open
Publication Date
5-2-2022
Volume
5
Issue
5
First Page
e2211363
Document Type
Open Access Publication
DOI
10.1001/jamanetworkopen.2022.11363
Rights and Permissions
Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. JAMA Netw Open. 2022 May 2;5(5):e2211363. doi: 10.1001/jamanetworkopen.2022.11363. This is an open access article distributed under the terms of the CC-BY License.
Recommended Citation
Xu, Kevin Y; Mintz, Carrie M; Presnall, Ned; Bierut, Laura J; and Grucza, Richard A, "Comparative effectiveness associated with buprenorphine and naltrexone in opioid use disorder and cooccurring polysubstance use." JAMA Network Open. 5, 5. e2211363 (2022).
https://digitalcommons.wustl.edu/oa_4/542
zoi220339supp1_prod_1651594518.74885.pdf (417 kB)
eMethods. Description of Conditional Logistic Regression eTable 1. Diagnosis Codes for OUD and Drug-Related Poisonings, Procedural Codes for OUD Treatment Services, and NDC Codes Used for Identification of OUD Pharmacy Claims eTable 2. Treatment Characteristics at the Individual Participant Level for All Individuals with a Primary Diagnosis of OUD and Acute Drug-Related Events During 1 Year Before and After Index Acute Event eTable 3. Treatment Characteristics at the Individual Participant Level for All Individuals with OUD eTable 4. Treatment Characteristics at the Individual Participant Level for Persons with OUD and Acute DrugRelated Poisonings, During 1 Year Before and After Index Event eTable 5. Distribution of Benzodiazepine and Statin Use During 1 Year Before and After Index Acute Drug-Related Poisoning eFigure. Sensitivity Analyses of Drug-Related Poisoning Associated with Opioid Use Disorder Treatment Days Compared with Nontreatment Days
eMethods. Description of Conditional Logistic Regression eTable 1. Diagnosis Codes for OUD and Drug-Related Poisonings, Procedural Codes for OUD Treatment Services, and NDC Codes Used for Identification of OUD Pharmacy Claims eTable 2. Treatment Characteristics at the Individual Participant Level for All Individuals with a Primary Diagnosis of OUD and Acute Drug-Related Events During 1 Year Before and After Index Acute Event eTable 3. Treatment Characteristics at the Individual Participant Level for All Individuals with OUD eTable 4. Treatment Characteristics at the Individual Participant Level for Persons with OUD and Acute DrugRelated Poisonings, During 1 Year Before and After Index Event eTable 5. Distribution of Benzodiazepine and Statin Use During 1 Year Before and After Index Acute Drug-Related Poisoning eFigure. Sensitivity Analyses of Drug-Related Poisoning Associated with Opioid Use Disorder Treatment Days Compared with Nontreatment Days
